chPD1-GITR CAR-T cells

chPD1-GITR CAR-T cells are an experimental chimeric antigen receptor (CAR) T-cell therapy designed to target solid tumors by leveraging the natural affinity of the Programmed Cell Death 1 (PD-1) receptor for its ligands, PD-L1 and PD-L2. The construct, referred to as a chimeric PD-1 (chPD1) receptor, consists of the extracellular domain of the murine PD-1 receptor fused to the CD3 zeta activation domain and a GITR (Glucocorticoid-induced TNFR-related protein) costimulatory domain. By using the PD-1 receptor itself as the antigen-binding moiety, these T cells can recognize a wide array of tumor types that express PD-L1 or PD-L2 as an immune evasion mechanism. In preclinical studies conducted at Longwood University, chPD1-GITR T cells were evaluated alongside other costimulatory variants (such as Dap10, CD28, and 4-1BB) across multiple murine cancer models, including melanoma, lymphoma, and various carcinomas. While the GITR-containing construct successfully induced T-cell proliferation and tumor cell lysis, comparative data indicated that the Dap10-containing variant provided superior anti-tumor efficacy and a more favorable pro-inflammatory cytokine profile.

Other names

chPD1-GITR T cellschPD-1-GITR T cellschPD 1-GITR T cellschimeric PD1-GITR T cells